

# Convulex®

CONTROL YOU CAN TRUST<sup>1-4</sup>



SUMMARY CARD

FOR VALPROATE

# CHECK LIST

- ✓ Information on the risks of valproate (CONVULEX®) use in female patients and pregnant women.
- ✓ Contraception and pregnancy prevention
- ✓ Annual Risk Acknowledgement Form
- ✓ Refer to the booklet for information for risk minimisation measures as part of the valproate Pregnancy Prevention Programme aimed at minimising pregnancy exposure during treatment with valproate.

**Please read the most up-to-date version of the Professional Information before prescribing valproate containing medicine**



**Reporting of suspected Adverse Events**  
Please report any suspected adverse events by email  
to [Drugsafety\\_ZA@arceralifesciences.com](mailto:Drugsafety_ZA@arceralifesciences.com)  
and SAHPRA to [adr@sahpra.org.za](mailto:adr@sahpra.org.za)



**References:** 1. Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. *J Clin Pharm Therap.* 2005;**30**:417-421. 2. Pelzl G, Mamoli B. Single Daily Dose of Valproic Acid: A Pharmacodynamic and Clinical Study. *Wien Klin Wochenshc.* 1992;**104**(10):286-289. 3. Vajda FJE. Valproate and neuroprotection. *J Clin Neurosci.* 2002;**9**(5):508-514. 4. Roberts D, Easter D, O'Bryan-Tear G. Epilim® Chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. *Biopharm Drug Dispos.* 1996;**17**:175-182.

For full prescribing information refer to the professional information approved by the Regulatory Authority.

**Convulex® 150/300/500 [Tablets]** COMPOSITION: Each tablet contains 150/300/500 mg valproic acid respectively. Registration Numbers: R/2.5/218; R/2.5/219; W/2.5/20

**Convulex® Syrup:** COMPOSITION: One ml contains 50 mg sodium valproate. Registration Number: W/2.5/390

Acino Pharma (Pty) Ltd., 106 16th Road, Midrand, South Africa. Tel: +27 11 516-1700. Africa | Acino. For Medical Information Enquiries kindly contact South Africa Medinfo: [Medinfo\\_ZA@arceralifesciences.com](mailto:Medinfo_ZA@arceralifesciences.com). Report adverse reactions to [Drugsafety\\_ZA@arceralifesciences.com](mailto:Drugsafety_ZA@arceralifesciences.com). AP806 09/2025. Exp 09/2027.